Legal & General Group Plc acquired a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 27,743 shares of the company’s stock, valued at approximately $1,746,000.
A number of other institutional investors and hedge funds also recently modified their holdings of TARS. Parallel Advisors LLC grew its position in shares of Tarsus Pharmaceuticals by 139.2% during the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock valued at $35,000 after buying an additional 291 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in Tarsus Pharmaceuticals by 367.1% in the first quarter. PNC Financial Services Group Inc. now owns 710 shares of the company’s stock worth $50,000 after acquiring an additional 558 shares during the last quarter. Comerica Bank boosted its stake in Tarsus Pharmaceuticals by 470.0% in the fourth quarter. Comerica Bank now owns 855 shares of the company’s stock valued at $70,000 after acquiring an additional 705 shares during the period. Truvestments Capital LLC boosted its stake in Tarsus Pharmaceuticals by 106.1% in the fourth quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock valued at $74,000 after acquiring an additional 468 shares during the period. Finally, Rockefeller Capital Management L.P. grew its holdings in shares of Tarsus Pharmaceuticals by 15.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after purchasing an additional 172 shares during the last quarter. 90.01% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on TARS. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Friday, July 17th. Guggenheim lowered their price objective on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating for the company in a research note on Tuesday, July 21st. HC Wainwright reiterated a “buy” rating and issued a $88.00 target price on shares of Tarsus Pharmaceuticals in a research note on Thursday, July 9th. Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Finally, Jefferies Financial Group raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday. Three investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Tarsus Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $90.50.
Tarsus Pharmaceuticals Price Performance
TARS opened at $90.78 on Monday. The stock’s 50 day moving average price is $66.01 and its 200 day moving average price is $65.96. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.20 and a quick ratio of 3.17. The stock has a market cap of $3.98 billion, a P/E ratio of -83.28 and a beta of 0.54. Tarsus Pharmaceuticals, Inc. has a 12 month low of $48.20 and a 12 month high of $91.53.
Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%.The business had revenue of $173.91 million for the quarter, compared to analyst estimates of $169.65 million. As a group, research analysts predict that Tarsus Pharmaceuticals, Inc. will post -2.06 earnings per share for the current year.
Insider Buying and Selling at Tarsus Pharmaceuticals
In other Tarsus Pharmaceuticals news, insider Jeffrey S. Farrow sold 14,396 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $60.95, for a total transaction of $877,436.20. Following the sale, the insider directly owned 56,801 shares in the company, valued at approximately $3,462,020.95. The trade was a 20.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Elizabeth Lin sold 1,590 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $80.00, for a total transaction of $127,200.00. Following the completion of the sale, the insider directly owned 4,770 shares of the company’s stock, valued at approximately $381,600. This represents a 25.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 51,428 shares of company stock valued at $3,350,810. 9.64% of the stock is currently owned by insiders.
Trending Headlines about Tarsus Pharmaceuticals
Here are the key news stories impacting Tarsus Pharmaceuticals this week:
- Positive Sentiment: Tarsus completed its acquisition of Alkeus, obtaining worldwide rights to gildeuretinol (ALK-001), an investigational once-daily oral treatment for Stargardt disease. The rare inherited eye disease has no FDA-approved therapy and may affect up to 86,000 people in the United States. Tarsus completes Alkeus acquisition
- Positive Sentiment: ALK-001 is being evaluated in the global NORTHSTAR Phase 3 trial and has received FDA Breakthrough Therapy, Orphan Drug, Fast Track and Rare Pediatric Disease designations. The regulatory designations and potential to address a significant unmet need strengthen Tarsus’ pipeline, although topline trial data are not expected until 2029. Alkeus acquisition adds Phase 3 program
- Positive Sentiment: Newly published TEASE-1 results showed that daily gildeuretinol significantly reduced the growth rate of retinal atrophic lesions versus an untreated group and was well tolerated, with no reported delays in dark adaptation or night blindness. TEASE-1 study results
- Neutral Sentiment: The acquisition expands Tarsus beyond its commercial XDEMVY business and supports management’s strategy of building a broader eye-care company. However, the transaction’s financial terms and the ultimate commercial value of ALK-001 were not detailed in the reports.
- Negative Sentiment: Insider Elizabeth Lin reported multiple sales totaling approximately $898,000 across September 1–2 under a pre-arranged Rule 10b5-1 trading plan. While such planned transactions may not reflect current management views, the sales add a modest cautionary signal for investors.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.
In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.
Read More
- Five stocks we like better than Tarsus Pharmaceuticals
- AI Token Costs Are Changing the Hardware vs. Software Debate
- 3 ETFs That Could Move as Rate Expectations Shift
- 3 Stocks With September Catalysts Investors Shouldn’t Ignore
- Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains
Want to see what other hedge funds are holding TARS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report).
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
